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ABSTRACT  10 
Preimplantation factor (PIF) is a pregnancy specific peptide with immune modulatory properties 11 
exerted on the human endometrium. Viable bovine embryos secrete PIF, but its effect on the 12 
bovine endometrial immune response is unknown, both in native and inflammatory stimulated 13 
endometrial tissue. An ex vivo bovine endometrial tissue culture model was used with 14 
lipopolysaccharide (LPS) as an inflammatory stimulant. The effect of synthetic PIF (sPIF) was 15 
assessed, in three separate experiments, on the secretion or mRNA expression of essential 16 
prostaglandins and cytokines. Radioimmunoassays were used to assess prostaglandin secretion 17 
and ELISA for IL-6 secretion from endometrial explants. mRNA expression of IL6 and IL8 was 18 
analysed from endometrial explants with real-time PCR. Synthetic PIF reduced native IL-6 19 
secretion from explants when pre-treated for 24 hours. There was no effect of sPIF on IL-6 20 
secretion from LPS challenged explants; however, sPIF increased IL6 mRNA expression when 21 
challenged with 500 ng/mL LPS. There was no effect of sPIF on prostaglandin secretion or 22 
mRNA expression of IL8. Therefore, sPIF is able to modulate the native IL-6 production 23 
pathway in the bovine endometrium, yet demonstrates no effect on prostaglandin secretion or IL8 24 
expression. Unlike in human studies, effects of sPIF were minimal, thus sPIF is not an effective 25 
modulator of the immune targets investigated in the bovine endometrium.  26 
Key words: endometrium; bovine; preimplantation factor; interleukin-6, prostaglandin F2α; 27 
prostaglandin E2 28 
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1. Introduction 30 
Preimplantation factor (PIF) is a 15 amino acid peptide that is produced by viable embryos as 31 
early as the two-cell stage [1]. Bovine embryos produce PIF both pre- and post-implantation [1, 32 
2].  Preimplantation factor works through an immune tolerance pathway in human pregnancy to 33 
facilitate the acceptance of the embryo by the mother [3, 4]. It is the action of this pathway that is 34 
of interest to studies of disease, as sPIF may have potential as an immune modulator. Applied to 35 
healthy human endometrium, sPIF is able to upregulate secretion of several interleukins, 36 
including IL-8 and IL-6 of decidualized stromal cells [5]. Interestingly, within a murine multiple 37 
sclerosis model, sPIF decreased the secretion of IL-6 from splenocytes in culture showing a 38 
tissue specific role of the peptide [6]. In a preliminary study, sPIF was investigated in an equine 39 
model of E. coli post-mating induced endometritis. It was shown that sPIF was able to reduce 40 
prostaglandin F2α (PGF2α) secretion from LPS induced explants 24 hours after challenge [7] but 41 
only in mares of the follicular stage of the oestrous cycle. More recently, in CD14+ cells, it has 42 
been demonstrated that sPIF does not directly interact with TLR-4, but specific downstream 43 
targets within the TLR-4 pathway [8]. As sPIF has been demonstrated to interact with the human 44 
endometrium in an immune modulatory manner, it was proposed that the peptide may act in a 45 
similar manner in the bovine endometrium. Furthermore, as uterine inflammation is a common 46 
cause of infertility in cattle through a dysregulation of endocrine function [9], it is of interest to 47 
investigate the role of sPIF as an immune modulator in an endometrial inflammatory 48 
environment. 49 
  Previous studies have utilised an ex vivo bovine model of normal and inflammatory 50 
endometrium, which shows responses similar to the whole cow [10, 11] and so this model 51 
provides a basis for this initial investigation. Both prostaglandins and interleukins are secreted by 52 
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cyclic, pregnant and inflammatory endometrial tissue and so have previously been used as targets 53 
to measure in ex vivo studies [10-12]. Prostaglandins are eicosanoid hormones produced by the 54 
endometrium and have essential functional roles in the bovine oestrous cycle and pregnancy [13, 55 
14]. Furthermore, both PGF2α and prostaglandin E2 (PGE2) are involved in the endometrial 56 
inflammatory response. Following a challenge with Escherichia coli-derived lipopolysaccharide 57 
(LPS), there is an increase in secretion of PGF2α and PGE2 from endometrial tissue explants [12, 58 
15]. Interleukins, such as IL-6 and IL-8 are demonstrated to be expressed during the oestrous 59 
cycle [16]. Furthermore, in ex vivo studies, IL-6 and IL-8 have been shown to have key roles 60 
within the endometrial innate immune response [11, 17].  61 
 The aim was to investigate the use of sPIF as a potential immune modulator within the 62 
bovine endometrium by assessing the role of the peptide using a previously developed 63 
endometrial tissue model, using LPS treatment to model an E. coli challenge [11, 12, 15]. It has 64 
already been demonstrated that sPIF does not bind to LPS [8]. It was hypothesised that sPIF 65 
would reduce key immune (IL-6 and IL-8) and endocrine (PGF2α and PGE2) factors in the bovine 66 
endometrium, at both a native and inflammatory level. 67 
2. Materials and methods 68 
2.1 Sample collection and endometrial explant culture 69 
As these experiments used post-slaughter material, licencing through the Animals (Scientific 70 
Procedures) Act 1986 and ethical review were not necessary. Bovine uteri and corresponding 71 
blood samples were collected from cows presented for slaughter at a local abattoir. A total of 46 72 
animals were used in the study. Uteri with stage I and IV ovaries were investigated to allow the 73 
study of sPIF on endometrial tissues that were not under the immune suppressive effects of 74 
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progesterone [18, 19]. Samples were staged by assessing ovarian morphology as previously 75 
described [20, 21]. Briefly, stage I was defined as having a newly ruptured corpus luteum with a 76 
diameter of 0.5 – 1.5 cm and stage IV as having a regressing corpus luteum with a diameter of < 77 
1 cm [20].  78 
Uteri and blood samples were stored on ice during the one-hour transportation to the 79 
laboratory. Tissues were used for explant culture and blood serum for analysis of progesterone 80 
concentration via ELISA (DRG Diagnostics, Marburg, Germany). To support ovarian 81 
morphology staging, the blood sera were used for progesterone analysis. For stage I and IV uteri, 82 
samples were deemed to have high progesterone if serum concentrations were above 1 ng/mL 83 
[10]. Progesterone inter- and intra- assay CVs were 8.66 % and 2.18 %, respectively. 84 
Tissue culture was established using the method previously described [11]. Briefly, tissue 85 
was sampled from the uterine horn ipsilateral to the staged ovary using an 8 mm biopsy punch. 86 
Samples were weighed and placed in 6 well plates (Corning, Amsterdam, The Netherlands) with 87 
3 mL of RPMI 1640 media (Gibco, Life Technologies, Paisley, UK) supplemented with 50 88 
IU/mL penicillin, 50 µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA) and 2.5 µg/mL 89 
amphotericin B (Sigma-Aldrich). All treatments were run in duplicate or triplicate and described 90 
for each experiment. Explants were incubated in a sterile incubator at 37oC and 5 % CO2 for up 91 
to 72 hours. Ultra-pure LPS from E. coli 0111:B4 strain was used (InvivoGen, Toulouse, 92 
France). Synthetic PIF (MVRIKPGSANKPSDD) was synthesised with > 95 % purity by 93 
Bioincept (New Jersey, USA). The amino acid structure of the human 15 amino acid PIF has 94 
previously been analysed and the 3D structure predicted [22]. The sPIF used in the present study 95 
is utilised in all research investigating sPIF. 96 
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2.2 Experiment 1 97 
The aim of experiment 1 was to investigate the effect of sPIF on prostaglandin and IL-6 secretion 98 
from bovine endometrial explants with and without an LPS challenge. Bovine stage IV uteri 99 
(n=14) were utilised. Preliminary studies from our laboratory, utilising unidentified cattle breeds, 100 
showed varied results in terms of prostaglandin secretion following sPIF treatment. Therefore, 101 
cattle were separated into two groups at the abattoir through identification of being either: beef 102 
heifers (n=7), unlikely to have been pregnant or; dairy type cows (n=7) and having had one or 103 
more pregnancies. Tissues were sampled from the endometrium and challenged with the 104 
following treatments in triplicate: control (media alone); LPS (1 µg/mL) alone; sPIF at three 105 
concentrations (50, 100 or 500 nM); or LPS (1 µg/mL) combined with each of the three sPIF 106 
concentrations. The LPS concentration was chosen based on previous studies utilising the same 107 
endometrial tissue model [11, 12]. Synthetic PIF concentrations were based on the previously 108 
described physiological range within the circulation during human pregnancy (50 and 100 nM) 109 
and one supra-physiological concentration (500 nM) [23]. Media supernatants were sampled 24, 110 
48 and 72 hours after challenge, from the same well at each time point. Time points of 24 and 48 111 
hours were chosen based on previous studies [11, 12] and 72 hours based on an equine 112 
endometrial explant study as a persistent infection time point [24]. Supernatant samples were 113 
stored at -20oC until analysed for PGF2α, PGE2 and IL-6.  114 
2.3 Experiment 2 115 
The aim of experiment 2 was to investigate the effect of a pre-treatment of sPIF on prostaglandin 116 
and IL-6 secretion from bovine endometrial explants with and without an LPS challenge and to 117 
ensure that there was no underlying inflammation in tracts that may cause variability in the 118 
results. Bovine stage I (n=12) and stage IV (n=12) uteri were utilised, as for experiment 1, split 119 
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into heifer (n=6 for each stage) or cow (n=6 for each stage) groups. To ensure there was no 120 
presence of sub-clinical inflammation, endometrial swabs were collected post-mortem using a 121 
modified cytobrush technique [25] and stained and fixed with Kwik-diff (Shandon, Thermo 122 
Scientific, Loughborough, UK) to test for inflammation. Samples were assessed for percentage 123 
of polymorphonuclear cells (PMN) by counting a minimum of 100 cells at X 400 magnification 124 
on Zeiss Axiovert 200M (Zeiss, Jena, Germany). Animals with a PMN percentage greater than 125 
5% were excluded based on the guidelines for the detection of subclinical endometritis [26, 27].  126 
Based on the results of experiment 1, the treatment protocol was modified so that 127 
explants were pre-treated with sPIF (50, 100 or 500 nM) or media alone (if explants were not to 128 
receive sPIF for the main treatment protocol) for 24 hours before challenging with LPS. At the 129 
end of the pre-treatment, the media supernatants were aspirated and replaced with fresh media 130 
alone or containing sPIF (50, 100 or 500 nM) or LPS (1 µg/mL) treatments as in experiment 1. 131 
Supernatant was sampled at 24 and 48 hours from different explant wells. No samples were 132 
collected 96 hours after the beginning of the pre-treatment (72 hours after LPS challenge) 133 
because integrity of tissue is likely to be compromised in serum free culture beyond 72 hours. 134 
Supernatant samples were stored at -20oC until analysed for PGF2α, PGE2 and IL-6.  135 
2.4 Experiment 3 136 
The aim of experiment 3 was to investigate the effect of a pre-treatment of sPIF on prostaglandin 137 
and IL-6 secretion and IL6 and IL8 mRNA expression in bovine endometrial explants, with and 138 
without three low dose LPS challenges to induce a less severe inflammatory response. Bovine 139 
stage I (n=4) and stage IV (n=4) uteri were utilised. Only tracts from cows (at least 1 previous 140 
pregnancy) were used. As in experiment 2, all tracts were swabbed using the cytobrush technique 141 
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and cytology examined for each tract to establish if there was any underlying inflammation. Any 142 
animals with greater than 5% PMNs present were discarded. 143 
 A 24 hour pre-treatment of sPIF or media alone was used, as in experiment 2. Based on 144 
the results of experiment 1 and 2 the treatment choices were modified to use lower 145 
concentrations of LPS (5, 50, 500 ng/mL). Although 1 µg/mL of LPS is a more commonly used 146 
dose in previous endometrial explant studies, these concentrations of LPS have also previously 147 
been shown to significantly induce PGF2α, PGE2 and IL-6 secretion from bovine endometrial 148 
explants or cells [11, 12]. One concentration of sPIF (100 nM) was used based on results from 149 
experiment 2. Explants were harvested 6 hours after treatment for determination of mRNA 150 
expression of IL6 and IL8. Supernatant was collected 24 hours after treatment from separate 151 
wells to determine IL-6 secretion. 152 
2.5 Prostaglandin radioimmunoassay and IL-6 ELISA 153 
Supernatant samples were analysed for PGF2α and PGE2 by radioimmunoassay (RIA) as 154 
described previously [28]. Antisera were a kind gift from Professor N. Poyser, University of 155 
Edinburgh and Professor Claire Wathes, The Royal Veterinary College. The limits of detection 156 
were 0.02 ng/mL for both assays. PGF2α inter- and intra- assay CVs were 12.8 % and 2.19 %, 157 
respectively. PGE2 inter- and intra- assay CVs were 12.69 % and 6.71 %, respectively.  158 
Supernatant samples were analysed for IL-6 concentration as described by the 159 
manufacturer (Bovine IL-6 ELISA; Thermo Fisher Scientific). The limit of detection was 75 160 
pg/mL and inter- and intra- assay CVs were 8.19 % and 5.99 %, respectively.  161 
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2.6 Real time PCR 162 
In experiment 3 where explants were analysed for gene expression, tissue pieces from each 163 
treatment were stored in RNAlater (Invitrogen, Life Technologies, Paisley, UK) and RNA 164 
extracted at a later date using the Total RNA purification kit (Norgen Biotek Corp, Ontario, 165 
Canada). From each sample, 1 µg RNA was treated for gDNA contamination with DNase I 166 
(Thermo Fisher Scientific, Loughborough, UK) and 250 ng subsequently reverse-transcribed to 167 
cDNA with the RevertAid First Strand cDNA synthesis kit (Thermo Fisher Scientific) according 168 
to the manufacturer’s instructions. Gene expression of IL6 and IL8 were analysed using SYBR 169 
Green RT-PCR, using Maxima SYBR Green/Rox qPCR master mix (Thermo Fisher Scientific) 170 
on a CFX connect (Bio-Rad, Hemel Hempstead, UK). Gene expression was normalised to two 171 
housekeeping genes, ACTB and 18s (of which expression was not altered by the experimental 172 
treatments) and then the control sample. All primers are outlined in Table 1.  173 
2.7 Statistical analysis 174 
Data were analysed using GenStat statistical software (14th edition, VSN International, Hemel 175 
Hempstead, UK) and reported as mean ± standard error of the mean (SEM). RIA and ELISA 176 
data were expressed as prostaglandin (ng) or interleukin (pg) secretion per mg of tissue, 177 
respectively and grouped into high or low progesterone groups where appropriate. Skewed data 178 
were transformed using log+1 or square root transformations in order to make the data normally 179 
distributed. Ratios of PGF2α to PGE2 secretion were calculated from the raw data within each 180 
experiment where prostaglandins were measured. Statistical significance was set at P<0.05 for all 181 
analyses and least significant difference (LSD) used as a post hoc significance test. A statistical 182 
tendency was defined as 0.05 < P < 0.1. The following analyses were completed for each 183 
experiment.  184 
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For experiment 1, a repeated measures ANOVA was performed to assess the effects of 185 
treatment, cattle type, progesterone and time. Cows were fitted as a random effect and time point 186 
as the repeated measure. Treatment and progesterone were initially used as the main treatments. 187 
Once it was established that there was no effect of progesterone, progesterone was removed as a 188 
main treatment. Treatment and cattle type were used as the main treatments for the main 189 
statistical analysis.  190 
A general ANOVA was performed to assess the effects of treatment, cattle type and 191 
progesterone for experiment 2 and treatment and progesterone for experiment 3. Stage I and 192 
stage IV explants were analysed separately. Cows were used as blocks, and each time point 193 
analysed separately. In experiment 2 treatment and progesterone were used as the main 194 
treatments, then progesterone removed and treatment and cattle type used as the main treatments 195 
for the main statistical analysis.  196 
3. Results 197 
3.1 Experiment 1 198 
3.1.1 Serum progesterone concentrations 199 
Samples were grouped in a high progesterone (HP) group if progesterone was greater than 1 200 
ng/mL (n=9), with the remaining samples in a low progesterone (LP) group (n=5). Mean 201 
progesterone concentrations for LP and HP were 0.27 ± 0.1 ng/mL and 13.86 ± 6.74 ng/mL, 202 
respectively. There was no significant effect of progesterone (P>0.05) on PGF2α, PGE2 or IL-6 203 
secretion; therefore, the factor of progesterone was removed from the analysis and results 204 
presented together.  205 
3.1.2 Prostaglandin F2α, E2 and IL-6 secretion from endometrial tissue 206 
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There was no interaction between sPIF treatment and cattle type (P>0.05) for prostaglandin or 207 
IL-6 secretion. LPS challenge increased (P<0.001) PGF2α, PGE2 and IL-6 secretion from 208 
explants at all time points (Fig 1). Synthetic PIF did not affect (P>0.05) PGF2α, PGE2 or IL-6 209 
secretion from explants with or without a LPS challenge (Fig 1). Synthetic PIF treatment had no 210 
effect on the ratio between PGF2α and PGE2 (P>0.05) at all time points, although LPS treatment 211 
alone increased the ratio, meaning that PGE2 secretion was favoured over PGF2α (P<0.05; data 212 
not shown). In explants not stimulated with LPS, IL-6 secretion was lower (P<0.05) with 213 
treatment of 100 nM sPIF compared with the 50 nM and 500 nM treatments (Fig 1c).  214 
3.2 Experiment 2 215 
Cytobrush smears showed that no cattle had subclinical inflammation as all samples had less 216 
than 5 % PMN. 217 
3.2.1 Serum progesterone concentrations 218 
 Stage I samples were assigned to the luteal high progesterone (LHP) group if progesterone 219 
concentrations were greater than 1 ng/mL (n=6), with the remaining samples allocated to a luteal 220 
low progesterone (LLP) group (n=6). Mean progesterone concentrations for LLP and LHP were 221 
0.66 ± 0.19 ng/mL and 8.2 ± 4.84 ng/mL, respectively.  222 
Stage IV samples were allocated to a follicular high progesterone (FHP) group if 223 
progesterone concentrations were greater than 1 ng/mL (FHP; n=7) with the remaining samples 224 
assigned to a follicular low progesterone group (FLP; n=5). Mean progesterone concentrations 225 
for FLP and FHP were 0.56 ± 0.13 ng/mL and 9.61 ± 3.18 ng/mL, respectively.   226 
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There was no effect of progesterone on PGF2α, PGE2 or IL-6 secretion within either stage 227 
I or IV explants  (P>0.05). Therefore, the factor of progesterone was removed and results 228 
displayed together. However, there was an interaction between progesterone group and 229 
treatments for PGF2α secretion in Stage I tissue at the 24 hour time point, with PGF2α secretion 230 
being significantly lower from LPS and PIF treated explants in the LLP group, compared to the 231 
equivalent treatments in the HLP group (P<0.05; data not shown). This particular interaction did 232 
not manifest itself in any of the other experiments.  233 
3.2.2 Prostaglandin F2α, E2 and IL-6 secretion from endometrial tissue  234 
There was no interaction (P>0.05) between sPIF treatment and cattle type in stage I cattle. LPS 235 
induced secretion (P<0.001) of PGF2α, PGE2 and IL-6 from explants at both 24 and 48 hours (Fig 236 
2). There was no effect (P<0.05) of sPIF on PGF2α or PGE2 secretion, with or without the 237 
presence of LPS (Fig 2). Synthetic PIF treatment of 50 and 100 nM reduced (P<0.05) the PGF2α 238 
to PGE2 secretion ratio compared with the control at 24 hours (Table 2), but not after 48 hours 239 
(P>0.05). The 500 nM sPIF treatment had no effect (P>0.05) on the PGF2α to PGE2 secretion 240 
ratio at either time point (Table 2). At 24 hours LPS treatment alone did not increase the PGF2α 241 
to PGE2 secretion ratio compared with the control, but LPS with 100 nM sPIF treatments did 242 
increase (P<0.05) the ratio from the control (Table 2). At 48 hours, LPS alone and in 243 
combination with all sPIF treatments increased (P<0.05) the PGF2α to PGE2 secretion ratio 244 
compared with the control (Table 2). Synthetic PIF at 100 and 500 nM reduced (P<0.05) native 245 
IL-6 secretion from unchallenged explants compared with the control at 24 hours (Fig 2c), but 246 
not at 48 hours (P>0.05; Fig 2f). There was no effect (P>0.05) of sPIF on IL-6 secretion from 247 
LPS stimulated explants (Fig 2). 248 
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In Stage IV cattle, there was no interaction (P>0.05) between sPIF treatment and cattle 249 
type. As with Stage I cattle, LPS induced (P<0.001) PGF2α, PGE2 and IL-6 secretion from 250 
explants at both 24 and 48 hours (Fig 3). There was no effect (P>0.05) of sPIF on PGF2α or PGE2 251 
secretion with or without the presence of LPS (Fig 3). Synthetic PIF alone had no effect (P>0.05) 252 
on the PGF2α to PGE2 secretion ratio (Table 3). At both time points, LPS alone and with all sPIF 253 
treatments increased (P<0.05) the PGF2α to PGE2 secretion ratio compared with the control 254 
(Table 3). However, as with Stage I cattle, sPIF at 100 nM reduced (P<0.05) IL-6 secretion 255 
compared with the control at 24 hours from explants that were not challenged with LPS (Fig 3c), 256 
but not at 48 hours (P>0.05; Fig 3f). There was no effect of sPIF on LPS stimulated explants 257 
(P>0.05; Fig 3). 258 
3.3 Experiment 3 259 
Cytobrush smears showed no cattle to have subclinical inflammation as all samples had less than 260 
5% PMN.  261 
3.3.1 Serum progesterone concentrations 262 
Stage I samples were assigned to the luteal high progesterone (LHP) group if progesterone 263 
concentrations were greater than 1 ng/mL (n=1), with the remaining samples allocated to a luteal 264 
low progesterone (LLP) group (n=3). Mean progesterone concentrations for LLP and LHP were 265 
0.59 ± 0.24 ng/mL and 1.88 ng/mL, respectively.  266 
Stage IV samples were allocated to a follicular high progesterone (FHP) group if 267 
progesterone concentrations were greater than 1 ng/mL (FHP; n=2) with the remaining samples 268 
assigned to a follicular low progesterone group (FLP; n=2). Mean progesterone concentrations 269 
for FLP and FHP were 0.13 ± 0.06 ng/mL and 3.88 ± 1.91 ng/mL, respectively.   270 
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There was no effect of progesterone on PGF2α, PGE2 or IL-6 secretion within either stage 271 
of cycle (P>0.05). Therefore, the factor of progesterone was removed and results displayed 272 
together. 273 
3.3.2 Expression of IL6 and IL8 in endometrial tissue 274 
IL6 and IL8 expression were increased (P<0.05) in both stage I and IV tissue following 50 and 275 
500 ng/mL LPS treatments (Fig 4). The treatment of 5 ng/mL LPS increased (P<0.01) IL6 gene 276 
expression in stage I tissue (Fig 4a). There was no effect (P>0.05) of 5 ng/mL LPS treatment on 277 
IL6 expression in stage IV tissue or IL8 expression in any tissue (Fig 4b, c, d).  278 
In stage IV tissue, when sPIF was added with 500 ng/mL LPS, IL6 gene expression was 279 
increased (P<0.05) compared with the expression induced by 500 ng/mL LPS treatment alone 280 
(Fig 4c). However, there was no effect (P>0.05) of sPIF treatment in combination with any other 281 
concentration of LPS or in the control samples in stage I or stage IV tissue (Fig 4a, c). 282 
Furthermore, there was no effect (P>0.05) of sPIF on IL8 expression in control or LPS treated 283 
samples (Fig 4b, d).  284 
3.3.3 IL-6 secretion from endometrial tissue 285 
IL-6 secretion from tissue not stimulated with LPS in stage I tissue was undetectable. All three 286 
concentrations of LPS induced (P<0.05) IL-6 secretion from stage IV explants at 24 hours (Fig 287 
5b). Only 50 and 500 ng/mL LPS treatments induced (P<0.001) IL-6 secretion from stage I 288 
explants (Fig 5a). There was no effect (P>0.05) of sPIF on IL-6 secretion from explants with or 289 
without LPS treatment (Fig 5). However, there was a statistical tendency (P<0.1) for sPIF to 290 
decrease IL-6 secretion from the 500 ng/mL LPS treatment in stage IV tissue only. 291 
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4. Discussion 292 
This is the first study to investigate the effects of sPIF within the bovine endometrium. Although 293 
by a small amount, sPIF significantly reduced IL-6 secretion from unstimulated stage I and stage 294 
IV endometrial explants when using a pre-treatment of sPIF, but not from LPS challenged 295 
explants. Conversely, sPIF increased IL6 mRNA expression from explants challenged with LPS, 296 
demonstrating possible differential effects of sPIF on mRNA expression and protein secretion, 297 
which needs further elucidation. There was no effect of sPIF on prostaglandin secretion from 298 
explants with or without LPS challenge. Heifers were separated from parous cows and cytobrush 299 
analysis on all tracts exhibited < 5% PMN, therefore any lack of effect was not attributed to 300 
whether the animal had previously been pregnant or had active inflammation in the uterus, 301 
respectively.  302 
The response of endometrial tissue to LPS in the present study is comparable to previous 303 
ex vivo studies [11, 12, 15]. LPS significantly induced PGF2α, PGE2, IL-6 secretion and 304 
expression and IL8 expression from bovine endometrial explants, as previously demonstrated in 305 
bovine endometrial tissue and cell culture [11, 12, 15, 17, 29]. Prostaglandin and IL-6 secretions 306 
were above the assay limits of detection unless otherwise stated in figures. There was little 307 
change in IL-6 secretion between 24 and 48 hours. Whether IL-6 was simply not secreted after 308 
this time point, or whether it was metabolised from the explant, was not clear and further 309 
evidence for explant metabolism relative to IL-6 is currently not available.   310 
 Synthetic PIF reduced native IL-6 secretion 24 hours post treatment from both stage I and 311 
IV explants at 100 nM and at 500 nM in stage I tissue. Yet there was no effect of sPIF on 312 
individual prostaglandin secretion. Synthetic PIF is demonstrated to function in a TLR-4 313 
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dependent manner in neuronal tissue [30, 31] and IL-6 is controlled directly through the TLR-4 314 
pathway, amongst other pathways. Within a multiple sclerosis model, murine splenocytes 315 
secreted less IL-6 and IL-17 into culture media following sPIF treatment compared with the 316 
disease control [32]. Furthermore, RAW 264.7 macrophages secrete less IL-6 and TNF-α, when 317 
cultured with sPIF, compared to both an unstimulated and irradiated control [33]. However, in 318 
decidualized human endometrial stromal cells, an increase in IL-6 protein expression was 319 
identified following sPIF treatment, converse to a decrease in IL-6 secretion in the present study 320 
[5]. IL-6 is known to be an important cytokine in the implantation period in humans, with 321 
maximum expression occurring at this point of the menstrual cycle [34]. In the pregnant bovine 322 
endometrium, IL6 mRNA expression, amongst other immune factors, has been demonstrated to 323 
be lower in the endometrium of heifers which carried a viable early stage embryo compared to 324 
those carrying a non-viable embryo, although expression was not compared to a reference native 325 
endometrium [35].  Yet, during pregnancy, there is a milieu of hormones and immune factors, 326 
such as interferon-τ, which circulate and modulate gene expression in the endometrium [36]. The 327 
present study has investigated the effects of sPIF on cyclic tissue and so, effects of pregnancy 328 
related hormones on the actions of sPIF need to be further elucidated.  329 
A 24 hour pre-treatment period was required to obtain an effect of sPIF on IL-6 secretion 330 
compared to the control. Previous human based studies have not used pre-treatment, but treated 331 
with sPIF for up to 24 hours [3, 5]. Yet, work on the human endometrium has only been 332 
completed on decidualized cells, which constitute the native environment for PIF within 333 
pregnancy [3, 5]. Decidua may be more responsive to sPIF as they are pregnancy specific. It is 334 
postulated that cyclic endometrial cells, not recently exposed to pregnancy signals, need a period 335 
of sPIF priming so that the peptide is able to modulate the uterine immune response.  336 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
When examining the effect of sPIF on LPS stimulated prostaglandin or IL-6 secretion in 337 
the present study, sPIF had no effect. Synthetic PIF has previously been shown to reduce nitric 338 
oxide production by macrophages, following LPS stimulation [31, 37], but this is the first study 339 
to investigate the effect of sPIF on the cytokine or prostaglandin secretion from the endometrium 340 
following LPS stimulation. As sPIF reduced native IL-6 secretion from tissue, it was considered 341 
whether the concentration of LPS was too high; a concentration of 1 µg/mL LPS may induce an 342 
acute immune response too extreme for sPIF to have an effect. Therefore, experiment 3 utilised 343 
three lower LPS concentrations based on a previous bovine endometrial explant study (5, 50 or 344 
500 ng/mL) [11]. There was no effect of sPIF on IL-6 secretion when explants were stimulated 345 
with these lower LPS concentrations, yet stage IV IL6 mRNA expression was up-regulated 346 
following treatment with sPIF and 500 ng/mL LPS. Moreover, in the same tissue, there was a 347 
statistical tendency for sPIF to decrease IL-6 secretion. Samples were collected at different time 348 
points, 6 hours for mRNA and 24 hours for protein secretion, to detect gene expression changes 349 
ahead of the down-stream expression of the corresponding protein secretion. Expression of IL6 is 350 
maximally increased at 6 hours post LPS challenge. Furthermore, expression of other cytokines, 351 
such as TNF and IL1B, are severely reduced by 24 hours post LPS treatment [17, 38]. Secreted 352 
IL-6 was sampled at 24 hours to show the accumulation of IL-6 throughout the innate immune 353 
response to the LPS challenge and is the general time point used in similar work [10, 11].  354 
The increase in IL6 mRNA expression following sPIF treatment in LPS stimulated tissue 355 
is supported by data from human endometrial stromal cells, where sPIF increased IL-6 secretion, 356 
although decidualized cells were used and so, are not directly comparable to the present study 357 
[5]. Yet there was a tendency for IL-6 secretion to decrease in tissue where mRNA expression 358 
increases following sPIF treatment. Synthetic PIF has been shown to alter the expression of 359 
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microRNA (miRNA) let-7, which represses translation of proteins and destabilises mRNA, in a 360 
TLR-4 dependent manner through the phosphatidylinositol-3 kinase/Akt pathway and 361 
subsequent destabilisation of the KH-type splicing regulatory protein, which also regulates 362 
several other miRNAs [31]. Such mechanisms of sPIF should be further studied in the bovine 363 
endometrium to assess the differential effects of sPIF on IL6 mRNA expression and subsequent 364 
protein secretion.  365 
There was no effect of sPIF on IL8 mRNA expression in experiment 3, with or without 366 
LPS treatment. Within decidualized human endometrial stromal cells, sPIF up-regulated IL-8 367 
protein secretion to a greater extent than that of IL-6 in the same study [5]. The disagreement 368 
with the present study may be due to one of several factors. Firstly, the cellular response to sPIF 369 
may be different, the present study used cyclic bovine endometrial tissue, whereas previous 370 
studies used decidualized human cells [5]. Additionally, the present study used whole tissue 371 
comprised of epithelial and stromal cells, compared with a culture of isolated stromal cells as 372 
used in human studies [5]. 373 
In the context of sPIF as an immune modulator within the bovine endometrium, the 374 
evidence provided here shows that sPIF has limited effects. Nonetheless, it would be of interest 375 
to determine the response of bovine endometrial stromal cells alone to sPIF, because postpartum 376 
stromal cells are intermittently exposed through the syndesmochorial placenta in bovine 377 
pregnancy.  378 
In conclusion, although to a small extent, sPIF significantly reduced native IL-6 secretion 379 
from healthy stage I and IV bovine endometrial explants following a 24 hour pre-treatment with 380 
sPIF. Furthermore, when stage IV explants were stimulated with 500 ng/mL LPS, sPIF increased 381 
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IL6 mRNA expression at 6 hours post treatment, following an initial 24 hour pre-treatment. 382 
There was no effect of sPIF on prostaglandin secretion from endometrial explants. Therefore, the 383 
present study demonstrates limited effects of the ability of sPIF to modulate key immune factors 384 
of bovine endometrial tissue.  385 
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Table 1. Primer sequences, amplicon length and accession numbers for ACTB, 18s, IL6 and IL8. All primers synthesised by Sigma-510 
Aldrich. 511 
 512 
Gene 
symbol 
Gene name Primer sequence Amplicon 
length (bp) 
Genbank 
accession number 
Reference 
ACTB Actin beta F - CAGAAGGACTCGTACGTGGG 
R - TTGGCCTTGGGGTTCAGGG 
199 NM_173979 Cronin, Turner [17] 
18SrRNA 18S ribosomal 
RNA 
F – CGGCGACGACCCATTCGAAC 
R - GAATCGAACCCTGATTCCCCGTC 
99 DQ222453.1 Wathes, Cheng [39] 
IL6 Interleukin-6 F – CTTCTGCTTTCCCTACCCCG 
R - CTCCAGAAGACCAGCAGTGG 
296 EU276071 
 
Designed using 
PrimerBLAST (Pub 
Med) 
IL8 Interleukin-8 F – GCAGGTATTTGTGAAGAGAGCTG 
R - CACAGAACATGAGGCACTGAA 
148 NM_173925 Cronin, Turner [17] 
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Table 2. Ratio of PGF2α to PGE2 secretion from all Stage I endometrial explants in experiment 2 513 
challenged with LPS and sPIF at 24 and 48 hours.  514 
a-e Means ± SEM within a time point, data not sharing a letter are significantly different (P<0.05). 515 
1
 Treatments: LPS = 1 µg/mL; sPIF 50 = 50 nM; sPIF 100 = 100 nM; sPIF 500 = 500 nM. 516 
Treatment1 
Time point 
24 hours 48 hours 
Control 1.30 ± 0.38abc 0.85 ± 0.25a 
LPS 1.70 ± 0.49ade 1.58 ± 0.46b 
sPIF 50  0.87 ± 0.25f 1.10 ± 0.32a 
sPIF 100 0.74 ± 0.21f 0.82 ± 0.24a 
sPIF 500 1.12 ± 0.32bcf 0.94 ± 0.27a 
LPS & sPIF 50 1.83 ± 0.53bd 1.90 ± 0.55b 
LPS & sPIF 100  2.01 ± 0.58d 1.73 ± 0.5b 
LPS & sPIF 500  1.53 ± 0.44abe 1.99 ± 0.57b 
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Table 3. Ratio of PGF2α to PGE2 secretion from all Stage IV endometrial explants in experiment 2 517 
challenged with LPS and sPIF at 24 and 48 hours. 518 
a-b Means ± SEM within a time point, data not sharing a letter are significantly different (P<0.05). 519 
1
 Treatments: LPS = 1 µg/mL; sPIF 50 = 50 nM; sPIF 100 = 100 nM; sPIF 500 = 500 nM. 520 
Treatment1 
Time point 
24 hours 48 hours 
Control 0.57 ± 0.13a 0.93 ± 0.29ab 
LPS 1.14 ± 0.2b 1.38 ± 0.26b 
sPIF 50 0.51 ± 0.1a 0.47 ± 0.08a 
sPIF 100 0.40 ± 0.07a 0.67 ± 0.18a 
sPIF 500 0.69 ± 0.17a 0.97 ± 0.26ab 
LPS & sPIF 50 1.29 ± 0.27b 1.45 ± 0.28b 
LPS & sPIF 100 1.44 ± 0.23b 1.49 ± 0.27b 
LPS & sPIF 500 1.56 ± 0.3b 1.42 ± 0.24b 
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Fig 1. Secretion of a) PGF2α, b) PGE2 and c) IL-6 from endometrial tissue explants in experiment 521 
1 challenged with LPS and sPIF at the same time, displayed as average across all time points (24, 522 
48 and 72 hours). Data are expressed as mean ± SEM. *** indicate significant differences from 523 
control (P<0.001).  Bars not sharing a letter are significantly different (P<0.05). 524 
Fig 2. Secretion of a,d) PGF2α; b,e) PGE2 and c,f) IL-6 from all Stage I endometrial tissue 525 
explants in experiment 2 following a pre-treatment of sPIF for 24 hours and then challenge with 526 
LPS and sPIF for 24 (a,b,c) and 48 hours (d,e,f). Data are expressed as mean ± SEM. * (P<0.05); 527 
*** (P<0.001) indicates significant differences from the control. 528 
Fig 3. Secretion of a,d) PGF2α; b,e) PGE2 and c,f) IL-6 from all Stage IV endometrial tissue 529 
explants in experiment 2 following a pre-treatment of sPIF for 24 hours and then challenge with 530 
LPS and sPIF for 24 (a,b,c) and 48 hours (d,e,f). Data are expressed as mean ± SEM. * (P<0.05), 531 
*** (P<0.001) indicates significant differences from the control. 532 
Fig 4. Expression of a,c) IL6 and b,d) IL8 in stage I (ab) and stage IV (c,d) endometrial tissue 533 
explants in experiment 3 following a pre-treatment of sPIF for 24 hours and then a challenge 534 
with three LPS concentrations alone (closed bars: 5, 50 and 500 ng/mL) or in combination with 535 
sPIF (open bars: 100 nM) for 6 hours. Expression was normalised against two housekeeping 536 
genes – ACTB and 18s for each sample (∆Cq). Data are expressed as mean ± SEM. * (P<0.05), 537 
** (P<0.01). *** (P<0.001) indicates significant differences from the control; within a graph, 538 
bars not sharing a letter are significantly different (P<0.05). 539 
Fig 5. Secretion of IL-6 from a) stage I, and b) stage IV endometrial tissue explants in 540 
experiment 3 following a pre-treatment of sPIF for 24 hours and then a challenge with three LPS 541 
concentrations (closed bars: 5, 50 and 500 ng/mL) and sPIF (open bars:100 nM) for 24 hours.  542 
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Data are expressed as mean ± SEM. * (P<0.05); ** (P<0.01) indicates significant differences 543 
from the control; bars not sharing a letter are significantly different (P<0.05). ND signifies no 544 
detection of IL-6 in the samples. 545 
  546 
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Revised 
Highlights 
• The effect of sPIF on bovine endometrial interleukins and prostaglandins was assessed. 
• A 24 hour pre-treatment with sPIF was needed to exert effects on the endometrium. 
• sPIF reduced native IL-6 secretion from the endometrium. 
• sPIF increased IL6 gene expression in LPS stimulated endometrial tissue. 
• There was no effect of sPIF on prostaglandin secretion or IL8 expression. 
